KPL-301 for Subjects With Giant Cell Arteritis

This Phase 2 randomized, double‐blind, placebo‐controlled proof of concept study will evaluate the efficacy and safety of mavrilimumab co‐administered with a 26‐week corticosteroid taper in subjects with GCA. The study will consist of a screening period (up to 6 weeks), a 26‐week double‐blind placebo‐controlled period during which subjects will receive blinded mavrilimumab or placebo co‐administered with a 26‐week corticosteroid taper, and a 12‐week washout safety follow‐up period during which subjects will discontinue and wash off blinded mavrilimumab or placebo.